MCEMP1 Inhibitors
MCEMP1 inhibitors constitute a group of chemical compounds that target various components of the cell cycle and transcription machinery. These inhibitors function primarily by disrupting the normal phosphorylation events that are essential for cell cycle progression and the initiation and elongation of transcription. By targeting CDKs involved in these processes, the inhibitors can lead to a reduction in the levels or activity of transcription factors and other regulatory proteins that are necessary for the optimal activity of MCEMP1. For instance, inhibitors like Alsterpaullone and Paullone, which target CDK1 and CDK2, could prevent the activation of transcription factors that enhance the function of MCEMP1, whereas Roscovitine's inhibition of CDK7 and CDK9 might lead to a reduction in transcriptional elongation of genes important for MCEMP1's role in the cell.
Further, the specificity of these inhibitors for certain CDKs can provide a means to indirectly affect MCEMP1 function. The selective inhibition of CDK4 and CDK6 by compounds such as Ribociclib, Palbociclib, and Abemaciclib can have significant implications for the regulation of the cell cycle and associated transcriptional processes. These CDKs are crucial in the transition from the G1 phase to the S phase of the cell cycle, where DNA replication occurs. By inhibiting CDK4 and CDK6, these compounds can induce a cell cycle arrest in the G1 phase, which in turn can lead to a decrease in the transcription of genes required for cell cycle progression, including those that may regulate or interact with MCEMP1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that targets CDKs involved in cell cycle regulation. By inhibiting CDK2, it can suppress the phosphorylation and activation of transcription factors that promote the expression of MCEMP1. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine selectively inhibits CDKs, especially CDK2, CDK7, and CDK9, which are critical for the transcription and RNA processing of many genes, including those that might enhance the expression of MCEMP1. | ||||||
Indirubin | 479-41-4 | sc-201531 sc-201531A | 5 mg 25 mg | $112.00 $515.00 | 4 | |
Indirubin, a derivative of indigo, is a potent inhibitor of CDKs and GSK-3, possibly influencing factors that regulate the stability and activity of proteins that control the level of MCEMP1. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol is an inhibitor of CDKs including CDK9, a component of the positive transcription elongation factor b (P-TEFb) complex, thereby potentially inhibiting the transcriptional elongation of genes involved in the activation of MCEMP1. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a potent and selective inhibitor of CDKs, particularly CDK1, CDK2, and CDK5, which could lead to a decrease in the transcriptional activity of genes that upregulate MCEMP1. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a selective inhibitor of several CDKs, with a preference for CDK1, CDK2, and CDK5, and can indirectly inhibit the expression of MCEMP1 by altering the phosphorylation status of transcription regulators. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib strongly inhibits CDK1, CDK2, CDK5, and CDK9, which could reduce the transcriptional activation of genes that are responsible for the expression of MCEMP1. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4 and CDK6, which are important for cell cycle progression and could indirectly affect the expression level of MCEMP1 by modulating the cell cycle. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of CDK4 and CDK6, similar to Ribociclib, and may lead to decreased synthesis of factors that enhance MCEMP1 expression by altering the cell cycle. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another selective inhibitor of CDK4 and CDK6, potentially reducing the expression of MCEMP1 by changing the phosphorylation status of proteins involved in the cell cycle and gene expression. | ||||||